Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Kewaunee Scientific (KEQU) Short-Term Debt repayments (2016 - 2026)

Kewaunee Scientific has reported Short-Term Debt repayments over the past 11 years, most recently at $11.0 million for Q1 2026.

  • Quarterly results put Short-Term Debt repayments at $11.0 million for Q1 2026, up 41.75% from a year ago — trailing twelve months through Jan 2026 was $15.6 million (down 85.78% YoY), and the annual figure for FY2025 was $75.6 million, down 49.11%.
  • Short-Term Debt repayments for Q1 2026 was $11.0 million at Kewaunee Scientific, up from $1.4 million in the prior quarter.
  • Over the last five years, Short-Term Debt repayments for KEQU hit a ceiling of $39.1 million in Q3 2023 and a floor of $1.4 million in Q4 2025.
  • Median Short-Term Debt repayments over the past 5 years was $21.4 million (2022), compared with a mean of $21.2 million.
  • Biggest five-year swings in Short-Term Debt repayments: skyrocketed 550.11% in 2023 and later plummeted 95.99% in 2025.
  • Kewaunee Scientific's Short-Term Debt repayments stood at $6.0 million in 2022, then surged by 526.63% to $37.7 million in 2023, then fell by 24.55% to $28.5 million in 2024, then plummeted by 95.24% to $1.4 million in 2025, then soared by 709.96% to $11.0 million in 2026.
  • The last three reported values for Short-Term Debt repayments were $11.0 million (Q1 2026), $1.4 million (Q4 2025), and $1.9 million (Q3 2025) per Business Quant data.